AVDL AVADEL PHARMACEUTICALS PLC US FDA Inspections 8-K Filing 2024 - FDA Review Update Avadel Pharmaceuticals confirmed that the FDA is still reviewing its Supplemental New Drug Application for LUMRYZ, aimed at treating narcolepsy in pediatric patients, with a target action date of September 7, 2024.Get access to all SEC 8-K filings of the AVADEL PHARMACEUTICALS PLC